US7133171055
© BusinessWire
09.12.2025
PEPG
LISTED
NASDAQ
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
PEPG
LISTED
NASDAQ
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than t...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
PEPG
LISTED
NASDAQ
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new composition of matter pa...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
12.11.2025
PEPG
LISTED
NASDAQ
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2025.
“This quarter was d...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
03.11.2025
PEPG
LISTED
NASDAQ
PepGen to Participate in Upcoming Investor Conferences
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:
Guggenheim Securities 2nd An...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
PEPG
LISTED
NASDAQ
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company’s data will be presented in two oral presentations at the 30th Annual International Congress of...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2025
PEPG
LISTED
NASDAQ
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the closing of its previously announced underwritten public offering of 35,937,500 shares of its common stock,...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
PEPG
LISTED
NASDAQ
PepGen Announces Pricing of $100 Million Public Offering
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 31,250,000 shares of its common stock at a price to the public of $3...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
PEPG
LISTED
NASDAQ
PepGen Announces Proposed Public Offering
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certa...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
PEPG
LISTED
NASDAQ
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced positive clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (...
Themefolio
Profiler
Peergroup
© BusinessWire
28.07.2025
PEPG
LISTED
NASDAQ
PEPG Deadline: Rosen Law Firm Urges PepGen Inc. (NASDAQ: PEPG) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) securities between March 7, 2024 and March 3, 2025. PepGen is a clinical-stage biotechnology company.
For more information, submit a form, email attorney Phillip...
Themefolio
Profiler
Peergroup
© BusinessWire
13.06.2025
PEPG
LISTED
NASDAQ
PEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit With Faruqi & Faruqi, LLP
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faru...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
10.06.2025
PEPG
LISTED
NASDAQ
PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PepGen Inc. (“PepGen” or “the Company”) (NASDAQ: PEPG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors w...
Themefolio
Profiler
Peergroup
© BusinessWire
10.06.2025
PEPG
LISTED
NASDAQ
Rosen Law Firm Urges PepGen Inc. (NASDAQ: PEPG) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of PepGen Inc. (NASDAQ: PEPG) securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). PepGen is a clinical-stage biotechnology company.
For more information, sub...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
PEPG
LISTED
NASDAQ
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, today announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping,...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
PEPG
LISTED
NASDAQ
PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
PEPG
LISTED
NASDAQ
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025.
“Our EDO platform’s uniq...
Themefolio
Profiler
Peergroup
© BusinessWire
02.04.2025
PEPG
LISTED
NASDAQ
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will present at the 24th Annual Needham Virtual Healthcar...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
PEPG
LISTED
NASDAQ
PepGen Announces Appointment of Two New Directors to its Board
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer ar...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
PEPG
LISTED
NASDAQ
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting two oral presentations as well as five posters at the 2025 Muscular Dystroph...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
PEPG
LISTED
NASDAQ
PepGen to Participate in Upcoming Investor Conferences
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:
Leerink Partners Global Heal...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
PEPG
LISTED
NASDAQ
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duche...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
PEPG
LISTED
NASDAQ
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2024, and recent corporate highlights.
“Today, we...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
PEPG
LISTED
NASDAQ
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial inv...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2025
PEPG
LISTED
NASDAQ
PepGen Announces CONNECT Program Updates
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) for p...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
PEPG
LISTED
NASDAQ
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding its...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
PEPG
LISTED
NASDAQ
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
PEPG
LISTED
NASDAQ
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2024.
“We are pleased with...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
PEPG
LISTED
NASDAQ
PepGen to Participate in Upcoming Investor Conferences
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:
Guggenheim's Inaugural Health...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
PEPG
LISTED
NASDAQ
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting a short oral presentation as well as five posters at the 29th Annual Congres...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2024
PEPG
LISTED
NASDAQ
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that Christopher Ashton, PhD, intends to retire from the Board of Directors effective September 30, 2024. Dr. As...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2024
PEPG
LISTED
NASDAQ
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2024
PEPG
LISTED
NASDAQ
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&am...
Themefolio
Profiler
Peergroup
© BusinessWire
11.08.2024
PEPG
LISTED
NASDAQ
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. (“PepGen” or “the Company”) (NASDAQ: PEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/PEPG.
Inve...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
